Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR - Get Free Report) have earned a consensus rating of "Buy" from the seven analysts that are presently covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have covered the stock in the last year is $8.86.

Several research analysts have recently weighed in on VOR shares. Wedbush reaffirmed an "outperform" rating and set a $7.00 price objective on shares of Vor Biopharma in a research report on Thursday, March 20th. Oppenheimer restated an "outperform" rating and issued a $8.00 price target on shares of Vor Biopharma in a research note on Friday, March 21st. HC Wainwright dropped their price objective on Vor Biopharma from $17.50 to $13.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Finally, Stifel Nicolaus decreased their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a "buy" rating for the company in a research note on Friday, March 21st.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Money Concepts Capital Corp increased its position in shares of Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the period. Two Sigma Investments LP raised its position in Vor Biopharma by 18.9% in the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after purchasing an additional 25,930 shares during the last quarter. Trustees of Columbia University in the City of New York acquired a new stake in shares of Vor Biopharma during the fourth quarter valued at about $102,000. RA Capital Management L.P. increased its stake in shares of Vor Biopharma by 74.3% in the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock valued at $44,007,000 after buying an additional 16,897,159 shares during the period. Finally, Northern Trust Corp raised its holdings in Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after buying an additional 44,252 shares during the last quarter. Institutional investors and hedge funds own 97.29% of the company's stock.

Vor Biopharma Price Performance

VOR traded down $0.03 during trading on Monday, reaching $0.73. The company had a trading volume of 155,307 shares, compared to its average volume of 587,319. The business's fifty day moving average price is $0.86 and its 200 day moving average price is $0.98. Vor Biopharma has a 12 month low of $0.49 and a 12 month high of $1.87. The company has a market cap of $91.27 million, a P/E ratio of -0.44 and a beta of -0.21.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.